NEW YORK (MedscapeWire) May 22 -- Although restricting oral intake has been a standard of care in acute pancreatitis, results of a randomized controlled trial presented on May 21 at the Digestive ...
As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating ...
Zacks Investment Research on MSN
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
CorMedix CRMD has experienced significant growth in 2025, fueled by the strong uptake of the company’s lead marketed drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback